Emboliner
Emboline Raises Over $10 Million in Series C Funding: Funds Raised To Be Used to Obtain Initial Commercial Approval of the Emboliner & Launch of a US IDE Clinical Study
xEmboline recently completed the 3-center, 31-patient SafePass 2 study of the Emboliner™ in New Zealand in which the device met all primary endpoints for safety and technical performance when used during TAVR.